Company intelligence / Profile preview

Tomwise

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Atomwise has nominated its first in-house AI-discovered development candidate, an orally bioavailable, allosteric TYK2 inhibitor, targeting inflammatory diseases. The platform has screened hundreds of targets, identifying novel hits in most cases. The company is transitioning from a service provider to a proprietary drug developer, with plans to enter clinical trials.

Therapeutic areas: ImmunologyRheumatologyGastroenterologyDermatologyOncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Sanofi (multi-target research collaboration)Hansoh Pharma (drug discovery partnership)Eli Lilly (drug discovery partnership)academic institutions via AIMS program

Beyond the preview

Go deeper on Tomwise.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tomwise.

Explore the full profile